IPO - Profile

Sana Biotechnology, Inc.

Health Care > Major Pharmaceuticals

SANA

Summary

We were founded on the belief that engineered cells will be one of the most important transformations in medicine over the next several decades. The burden of diseases that can be addressed at their root cause through engineered cells is significant. We view engineered cells as having the potential to be as therapeutically disruptive as biologics to clinical practice. Our long-term aspirations are to be able to control or modify any gene in the body, to replace any cell that is damaged or missing, and to markedly improve access to More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$25.00 23,500,000 Positive High 37.82%

Offering Team

  • Legal counsel
  • Cooley LLP
  • Auditors
  • Ernst & Young LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 03 Feb, 2021

Offer 04 Feb, 2021

Look Ahead

Lock Up Expiry Aug 04, 2021

IPO Terms

Offer Price $25.00
Offer Size 23M

Market Sentiments

Stock Price